Clinical trials: Antithrombotic
Acute Coronary Syndrome, Atrial Fibrillation
Management of Antithrombotic TherApy in Patients With Atrial Fibrillation or DevelOping AtRial Fibrillation During Hospitalization for PCI
ACS are a potent risk factor for AF, with new onset AF occurring in up to 1 in every 5 patients hospitalized with an ACS. Despite its relatively frequent occurrence and the many etiologic factors involved in its pathogenetic…
- Trial name
- Matador-PCI (NCT03656523)
- Testing
- Acute coronary syndrome and PCI and AF
- Where
- 76 sites in Italy
- Volunteers
- 598 people
- Sponsor
- Heart Care Foundation
Cerebrovascular Trauma
Natural History and Nonoperative Management of Penetrating Cerebrovascular Injury
The goal of this study is to evaluate a series of cases of penetrating cerebrovascular injury managed without upfront operation.
- Trial name
- NCT05305690
- Testing
- No intervention
- Volunteers
- 20 people
- Sponsor
- Poudre Valley Health System
Cervical Artery Dissection
Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
Primary objective: To demonstrate the non-inferiority of acetylsalicylic acid (ASA) to anticoagulant treatment (vitamin K antagonists) in CAD-patients with regard to outcome and complication measures.
- Trial name
- TREAT-CAD (NCT02046460)
- Testing
- Acetylsalicylic acid, Vitamin K antagonist
- Where
- 10 sites in Denmark, Germany and 1 more
- Volunteers
- 194 people
- Sponsor
- Stefan Engelter
GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Anticoagulation After GI Bleeding Pilot Study and Registry
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related…
- Trial name
- PANTHER-GI (NCT05290857)
- Testing
- Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Comatose
Ticagrelor for the Comatose
The study will investigate the effect of the oral antiplatelet agent ticagrelor (Brilique) when it is administrated through a nasogastric tube in comatose patients.
- Trial name
- TICOMA (NCT02175875)
- Where
- Denmark
- Volunteers
- 47 people
- Sponsor
- Lene Holmvang
Acute Coronary Syndrome (ACS)
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.
- Trial name
- ISAR-REACT 5 (NCT01944800)
- Testing
- Ticagrelor, Prasugrel
- Where
- 19 sites in Germany, Italy
- Volunteers
- 4,018 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Mild Head Injury, Anticoagulant
Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
Head trauma is a common injury in emergency department. Investigation to search for complication is guided by the clinical examination and the case history, such as taking anti-thrombotics.
- Conditions
- Mild Head Injury, Anticoagulant, Antiplatelet
- Trial name
- ISTCAT (NCT04305821)
- Testing
- Dosage of S100β protein
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Rennes University Hospital
Hemorrhage
Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliative Care Unit
Even if most patients in palliative care units presented with well-recognized risks factors of venous thromboembolism (VTE) (eg: active cancer, bed rest, previous history of venous thrombosis), the incidence of VTE in palliative…
- Trial name
- RHESO (NCT01056978)
- Where
- 20 sites in France
- Volunteers
- 1,230 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Nonvalvular Atrial Fibrillation, Aspirin
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet…
- Conditions
- Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy, High Bleeding Risk
- Trial name
- NCT07125417
- Testing
- Single Antiplatelet Therapy or No Therapy (Control), Non-Antithrombotic Therapy
- Where
- 21 sites in Japan
- Volunteers
- 500 people
- Sponsor
- OCEAN-SHD Study Group
Patent Foramen Ovale, Ischemic Stroke
Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
- Conditions
- Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer
- Trial name
- HALTI (NCT04475510)
- Testing
- Antiplatelet treatment discontinuation
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Josep Rodes-Cabau
Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia
Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia
The goal of this study is to learn if a new medicine (called antiplatelet and anticoagulant [APAC]) can help the body to prevent blood clots and whether APAC is safe and well tolerated in patients with blocked or narrowed…
- Trial name
- HEALING (NCT07352800)
- Testing
- APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg,
- Where
- 3 sites in Finland
- Volunteers
- 42 people
- Sponsor
- Aplagon Oy
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Aortic Valve Disease, Myocardial Infarction
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
At present, a variety of antithrombotic regimens are prescribed in the early postprocedure period after transcatheter aortic valve implantation (TAVI).
- Conditions
- Aortic Valve Disease, Myocardial Infarction, Stroke, Bleeding
- Trial name
- POPular-TAVI (NCT02247128)
- Testing
- Aspirin + clopidogrel, Aspirin monotherapy, OAC + clopicogrel
- Where
- 17 sites in Belgium, Czechia and 2 more
- Volunteers
- 1,016 people
- Sponsor
- St. Antonius Hospital
Antiphospholipid Syndrome, Arterial Thrombosis
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12…
- Trial name
- NCT05646394
- Testing
- Dual antiplatelet therapy, Combined antithrombotic therapy, Vitamin K antagonist standard intensity
- Where
- 3 sites in Argentina, Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
In-hospital Falls
In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital
Anticoagulant and antiplatelet treatments have well defined indactions, with a clearly proved benefit, respectivly for prevention of arterial and venous emblism and for prevention of athermo-related arterial thrombosis.
- Trial name
- HEMO-CIH (NCT03687541)
- Where
- France
- Volunteers
- 157 people
- Sponsor
- Rennes University Hospital
Acute Coronary Syndrome
REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients
RE-ACT is a national, multi-centre, observational, prospective, longitudinal cohort study which will include patients hospitalized for ACS within 24 hours of symptom onset and who have a final diagnosis of ST-segment elevation…
- Trial name
- RE-ACT (NCT02001545)
- Where
- 8 sites in Bulgaria
- Volunteers
- 814 people
- Sponsor
- AstraZeneca
Intracerebral Hemorrhage, Hemorrhagic Risk Conditions
Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is associated with high mortality and long-term disability, and effective treatment options remain limited.
- Conditions
- Intracerebral Hemorrhage, Hemorrhagic Risk Conditions, Bleeding Disorders
- Trial name
- MIMICK-TIPITCH (NCT07411079)
- Testing
- Ex vivo exposure to modified rtPA
- Where
- France
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Cardiovascular Diseases
Antithrombotic Activities of a Novel Yoghurt Drink: a Postprandial Study
The project aims to investigate the antithrombotic activity of the novel yoghurt drink enriched with polar lipids derived from ovine milk.
- Trial name
- NCT05290883
- Testing
- Novel yoghurt drink containing Polar Lipids
- Where
- Ireland
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Limerick
Acute Coronary Syndrome
Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes
Phase-3, randomized, multicenter, parallel-group study with blind evaluation of endpoints and intention-to-treat analysis. The general purpose of the study is evaluate the non-inferiority hypothesis for ischemic events and the…
- Trial name
- NEOMINDSET (NCT04360720)
- Testing
- Antiplatelet Monotherapy
- Where
- 50 sites in Brazil
- Volunteers
- 3,410 people
- Sponsor
- Hospital Israelita Albert Einstein